Cargando…

Retrospective Review of Outcomes of Multiple Myeloma (MM) Patients With COVID-19 Infection (Two-Center Study)

INTRODUCTION: COVID-19 has profound effects on patients with multiple myeloma (MM) mainly due to underlying immune dysfunction and associated therapies leading to increased susceptibility to infections. The overall risk of morbidity and mortality (M&M) in MM patients due to COVID-19 infection is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ehsan, Hamid, Britt, Alec, Voorhees, Peter M, Paul, Barry, Bhutani, Manisha, Varga, Cindy, Chiad, Zane, Ragon, Brittany K., Abdallah, Al-Ola A., Ahmed, Nausheen, Atrash, Shebli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2023
Materias:	Original Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847363/ https://www.ncbi.nlm.nih.gov/pubmed/36797155 http://dx.doi.org/10.1016/j.clml.2023.01.006

Ejemplares similares

Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma
por: Foureau, David M., et al.
Publicado: (2023)

Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma
por: Foureau, David, et al.
Publicado: (2021)

Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexamethasone
por: Alkharabsheh, Omar, et al.
Publicado: (2023)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

Clinical Presentation and Gene Expression Profiling of Immunoglobulin M Multiple Myeloma Compared With Other Myeloma Subtypes and Waldenström Macroglobulinemia
por: Atrash, Shebli, et al.
Publicado: (2017)

Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease
por: Abdallah, Al‐Ola, et al.
Publicado: (2021)

Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma
por: Atrash, Shebli, et al.
Publicado: (2018)

Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma
por: Foureau, David M., et al.
Publicado: (2020)

A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma
por: Atrash, Shebli, et al.
Publicado: (2021)

Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed Therapy
por: Atrash, Shebli, et al.
Publicado: (2023)

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
por: Friend, Reed, et al.
Publicado: (2017)

Unilateral conjunctival AL kappa amyloidosis with trace evidence of systemic amyloidosis
por: Abdallah, Al-Ola, et al.
Publicado: (2012)

The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma
por: Tariq, Syed Maaz, et al.
Publicado: (2023)

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
por: Atrash, S, et al.
Publicado: (2015)

Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis
por: Atrash, Shebli, et al.
Publicado: (2022)

MM-219: Outcome of COVID-19 Among Patients with Multiple Myeloma at the Armenian Hematology Center
por: Sahakyan, Lusine, et al.
Publicado: (2021)

Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
por: ATRASH, Shebli, et al.
Publicado: (2021)

Influence of gut microbiome on multiple myeloma: friend or foe?
por: Ahmed, Nausheen, et al.
Publicado: (2020)

Correction to: Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
por: Atrash, Shebli, et al.
Publicado: (2021)

Poster: MM-219: Outcome of COVID-19 Among Patients with Multiple Myeloma at the Armenian Hematology Center
por: Sahakyan, Lusine, et al.
Publicado: (2021)

Neutralizing Antibody Responses Against Sars-Cov-2 in Patients with Plasma Cell Disorders Who Are on Active Treatment after Two Doses of mRNA Vaccination
por: Abdallah, Al-Ola, et al.
Publicado: (2021)

Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
por: McCurdy, Arleigh, et al.
Publicado: (2023)

Complement Regulatory Genetic Mutations in the Setting of Autoimmune Thrombotic Thrombocytopenic Purpura: A Case Series
por: Atrash, Shebli, et al.
Publicado: (2017)

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials
por: Paiva, Bruno, et al.
Publicado: (2023)

MM-239: A Tertiary Center Experience of Multiple Myeloma Patients with COVID-19: Lessons Learned and the Path Forward
por: Wang, Bo, et al.
Publicado: (2020)

Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma
por: Gil, Kellen, et al.
Publicado: (2022)

Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
por: McCurdy, Arleigh, et al.
Publicado: (2023)

Inhibitor of Apoptosis Proteins (IAPs) as therapeutic targets in Multiple Myeloma (MM)
por: Ramakrishnan, Vijay, et al.
Publicado: (2014)

The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies
por: Hernández-Rivas, José-Ángel, et al.
Publicado: (2022)

The Metabolic Features of Osteoblasts: Implications for Multiple Myeloma (MM) Bone Disease
por: Lungu, Oxana, et al.
Publicado: (2023)

PB2140: EVALUATION OF EARLY RELAPSE IN MULTIPLE MYELOMA (MM) PATIENTS
por: Gkioka, Annita-Ioanna, et al.
Publicado: (2023)

Chronic Lymphocytic Leukemia with Translocation (2;14)(p16;q32): A Case Report and Review of the Literature
por: Socola, Francisco, et al.
Publicado: (2016)

P860: CIRCULATING MULTIPLE MYELOMA CELLS (CMMCS) AS PROGNOSTIC FACTOR AND MINIMAL RESIDUAL DISEASE MARKER IN MM AND SMOULDERING MM PATIENTS
por: Vigliotta, Ilaria, et al.
Publicado: (2023)

Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM)
por: Tibullo, Daniele, et al.
Publicado: (2016)

“Waitlist mortality” is high for myeloma patients with limited access to BCMA therapy
por: Ahmed, Nausheen, et al.
Publicado: (2023)

Ascorbic Acid Augments Arsenic-Mediated Cell Death in Multiple Myeloma (MM) Cells
por: Grad, Jennifer M., et al.
Publicado: (2001)

Connect MM Registry as a national reference for United States multiple myeloma patients
por: Ailawadhi, Sikander, et al.
Publicado: (2019)

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
por: Bahlis, Nizar J., et al.
Publicado: (2023)

P1685: PATIENTS’ PREFERENCES FOR MULTIPLE MYELOMA (MM) TREATMENT INITIATION AND DISCONTINUATION IN THE US
por: Binder, Adam F., et al.
Publicado: (2023)

BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice
por: Hamouda, Mohamed-Amine, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6do76bnnennf0ofgbid4fbn1i8